Discover more from PsyMed Ventures Newsletter
Investing in Neurotech 101: Alex Morgan of Khosla Ventures
Business Trip by PsyMed Ventures, a podcast exploring the future of mental health & wellness
Advancements in neuroscience, AI, and bioengineering are unlocking new possibilities for neurotechnologies. Investors are paying attention.
Greg and Matias interview Alex Morgan of Khosla Ventures, one of the most active investors in neurotech startups. As an MD, PhD, and physicist, he brings unique technical expertise to evaluating the emerging ecosystem. He's backed companies harnessing neuromodulation for varied applications - from sleep to depression to motor recovery.
According to Alex, we are at an inflection point where advances in areas like brain-computer interfaces, electrical stimulation, and digital therapeutics will enable more personalized and effective mental healthcare.
In this episode we discuss:
When neurotech makes more sense than pharma
How to identify and evaluate promising neurotech startups
When you should go the consumer vs. FDA route
What makes a strong neurotech founding team
Once you've finished the episode, we'd love to hear your thoughts! Tweet us at @psymedventures to share your views.
P.S. Do you know someone who would enjoy the Business Trip by PsyMed Ventures podcast? Feel free to share this newsletter by clicking the link below and hitting the ❤️ button on this post to help us reach more people on Substack 🙏